Sonoma Pharmaceuticals Turns EBITDA Positive for First Time with Record Quarterly Revenue - Sonoma Pharma
Sonoma Pharmaceuticals reported first-quarter revenue of $6.4 million, up from $4.0 million a year earlier, with U.S. sales up 141% to drive growth. Gross profit rose to $2.6 million (40% margin). EBITDA turned positive at $0.1 million versus a $1.0 million loss. Cash was $5.3 million as of June 30, 2026. Shares rose to $1.24 premarket.
How this was made
The 30-second read
Why it matters
The disclosed financial metrics (revenue growth, gross margin up to 40%, EBITDA turning positive) are likely to influence near-term valuation and sentiment, especially given the same-day premarket jump.
Market read
A single-name earnings-style update with a clear profitability milestone and same-day price reaction.
What to watch
The article does not provide guidance, cash burn trajectory beyond cash balance, or detailed operating expense drivers, so traders should verify whether operating leverage is durable.
Background
Sonoma Pharmaceuticals described a profitability inflection, citing record quarterly revenue, margin expansion, and first positive EBITDA.
Ticker impact
Sonoma Pharmaceuticals reported record quarterly revenue of $6.4M and first-ever positive EBITDA of $0.1M, driving premarket shares up 9.73%.
Bullish bias for follow-through, but magnitude likely depends on whether the EBITDA inflection is sustained in subsequent quarters.
The article discloses multiple earnings-style datapoints (revenue, gross margin, EBITDA turning positive) plus same-day premarket price reaction, which together are actionable for positioning and risk management.
Market effects
Microcap pharma/OTC-distributor models may see sentiment lift when EBITDA turns positive, but this is company-specific.
No direct regional macro read-through beyond reported Asia and Latin America shipment timing effects.
Limited broader market impact; primarily a single-name fundamental update.
Counterpoint
Positive EBITDA of $0.1M on $6.4M revenue could be fragile, and quarterly shipment timing (Asia/Rest of World, Latin America order timing) may make results less repeatable.
Key entities
- companySonoma Pharmaceuticals
Reported record quarterly revenue and first positive EBITDA, with premarket shares up 9.73%.
- executiveAmy Trombly
CEO quoted on the inflection point, FDA clearances, distribution partnerships, and pipeline of commercial opportunities.
